Journal of Chemotherapy最新文献_第3页

Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco). 每周服用三次的替可普兰：一种满足现代需求的老药。它在曼佐尼医院（莱科）传染病科作为门诊肠外抗生素治疗（OPAT）的应用经验。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2025-10-22 DOI: 10.1080/1120009X.2025.2575226

Valentina Morena, Federico Conti, Dario Cattaneo, Benedetta Trentacapilli, Martina Bottanelli, Lucia Bradanini, Annacarla Chiesa, Nicole Gemignani, Chiara Molteni, Alessandro Pandolfo, Sara Volpi, Alessandra Consonni, Giada Valesecchi, Silvia Pontiggia, Stefania Piconi

{"title":"Thrice-weekly teicoplanin: an old drug for modern needs. Experience of its use as outpatient parenteral antibiotic therapy (OPAT) at infectious disease unit of Manzoni hospital (Lecco).","authors":"Valentina Morena, Federico Conti, Dario Cattaneo, Benedetta Trentacapilli, Martina Bottanelli, Lucia Bradanini, Annacarla Chiesa, Nicole Gemignani, Chiara Molteni, Alessandro Pandolfo, Sara Volpi, Alessandra Consonni, Giada Valesecchi, Silvia Pontiggia, Stefania Piconi","doi":"10.1080/1120009X.2025.2575226","DOIUrl":"10.1080/1120009X.2025.2575226","url":null,"abstract":"Teicoplanin is a glycopeptide antibiotic with a long elimination half-life (50 hours) that allows administration thrice a week, though it is approved for daily use. The aim of this retrospective, single-arm study is to assess the clinical outcome of using thrice-weekly teicoplanin (TWT) as outpatient parenteral antibiotic therapy (OPAT) for deep (DSIs) and non-deep-seated infections (NDSIs). We included 37 outpatients (25 with DSIs and 12 with NDSIs) treated with TWT between 01/2021 and 10/2023. The outcome was favorable in 78% of them (80% with DSI, 75% with NDSIs) and Therapeutic drug monitoring (TDM) was performed in all cases. 8 patients required dosage modification because of inadequate trough levels; they were younger and had a higher creatinine clearance. 6/37 patients experienced adverse events, mostly skin rash (4/6). TWT can be a good option for OPAT; its pharmacokinetic reduces the number of hospital accesses and TDM permits to tailor the dosage.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"447-454"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. 晚期非小细胞肺癌患者免疫检查点抑制剂类型对生存率的影响

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2025-06-28 DOI: 10.1080/1120009X.2025.2524914

Tetsuo Shimizu, Masayuki Nomoto, Yoshiko Nakagawa, Yasuhiro Gon

引用次数: 0

Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia. 确定与生存相关的遗传生物标志物，以发现急性髓性白血病的新治疗靶点。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2025-07-05 DOI: 10.1080/1120009X.2025.2527464

Cansu Ergun, Yağmur Kiraz, Gizem Ayna Duran

{"title":"Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia.","authors":"Cansu Ergun, Yağmur Kiraz, Gizem Ayna Duran","doi":"10.1080/1120009X.2025.2527464","DOIUrl":"10.1080/1120009X.2025.2527464","url":null,"abstract":"Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"474-490"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy. 靶向谷氨酰胺酶（GLS）抑制CXCL8分泌并使食管鳞状细胞癌对免疫治疗增敏。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 DOI: 10.1080/1120009X.2026.2722740

Xiu Zhang, Jiang Chao, Zhuqing Ji, Kai Chen

{"title":"Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy.","authors":"Xiu Zhang, Jiang Chao, Zhuqing Ji, Kai Chen","doi":"10.1080/1120009X.2026.2722740","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2722740","url":null,"abstract":"Immune checkpoint inhibitor (ICI) resistance remains a major challenge in esophageal squamous cell carcinoma (ESCC). This study investigates the role of glutaminase (GLS) in modulating the tumor immune microenvironment and its impact on immunotherapy response. Bioinformatic analysis of TCGA data revealed an inverse correlation between GLS expression and CD8+ T cell infiltration. In ESCC clinical specimens, high GLS expression correlated with elevated CXCL8 levels and reduced CD8+ T cell infiltration. Mechanistically, our data support an association between GLS expression and increased CXCL8 transcription, accompanied, at least in part, by HAT-dependent enhancement of H3K27 acetylation at the CXCL8 promoter region. In advanced ESCC patients receiving immunochemotherapy, high tumoral GLS expression was associated with significantly shorter progression-free survival. In vitro and in vivo functional studies showed that GLS knockdown in ESCC cells was associated with enhanced T-cell effector cytokine secretion, increased tumor infiltration of CD8+ T cells, and greater tumor suppression when combined with anti-PD-1 therapy in a humanized mouse model. Importantly, exogenous CXCL8 supplementation partially reversed the increased Granzyme B and IFNγ secretion induced by GLS knockdown in the co-culture system, supporting a functional role for CXCL8 in GLS-associated immune suppression. These results support a model in which GLS contributes to an immunosuppressive microenvironment in ESCC, at least in part through epigenetic upregulation of CXCL8. These findings support further investigation of GLS targeting as a potential strategy to improve immunotherapy response in ESCC.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-17"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress on eravacycline: from pharmacokinetics/pharmacodynamics to the practice of individualized therapy. 依瓦环素的研究进展：从药代动力学/药效学到个体化治疗的实践。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2026-05-10 DOI: 10.1080/1120009X.2026.2668274

Chao Meng, Jingjing Lan, Shuaijia Wang, Xianran Liu, Yalin Dong, Siying Chen

{"title":"Research progress on eravacycline: from pharmacokinetics/pharmacodynamics to the practice of individualized therapy.","authors":"Chao Meng, Jingjing Lan, Shuaijia Wang, Xianran Liu, Yalin Dong, Siying Chen","doi":"10.1080/1120009X.2026.2668274","DOIUrl":"10.1080/1120009X.2026.2668274","url":null,"abstract":"Eravacycline is a fully synthetic, fluorinated third-generation tetracycline with broad-spectrum antibacterial activity, approved for the treatment of complicated intra-abdominal infections(cIAI). Clinical studies have demonstrated favorable safety and predictable pharmacokinetic properties, supporting its use in diverse complicated infections. With increasing application in critically ill patients and those with significant organ dysfunction, increasing attention has been directed toward the potential alterations in pharmacokinetics caused by pathophysiological changes in these populations. Such variability may influence drug exposure and treatment outcomes; however, current dosing strategies largely follow standard recommendations, and evidence supporting dose optimization in special populations remains limited. This review provides a comprehensive overview of current evidence regarding the chemical structure, antimicrobial and pharmacological properties, pharmacokinetics, pharmacokinetic/pharmacodynamic characteristics, clinical applications, population pharmacokinetics, and therapeutic drug monitoring of eravacycline, aiming to support rational clinical use and individualized dosing strategies.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"415-431"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation. 早期达拉图单抗为基础的治疗在复发和难治性多发性骨髓瘤患者中显示出显著的有效性：一项真实世界的回顾性调查。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2025-07-29 DOI: 10.1080/1120009X.2025.2540172

Yi Chen, Qinyun Cai, Zongjian Qiu, Haili Geng, Yang Li, Rong Zhan, Zhihong Zheng

{"title":"Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.","authors":"Yi Chen, Qinyun Cai, Zongjian Qiu, Haili Geng, Yang Li, Rong Zhan, Zhihong Zheng","doi":"10.1080/1120009X.2025.2540172","DOIUrl":"10.1080/1120009X.2025.2540172","url":null,"abstract":"This research aimed to assess the effectiveness of daratumumab in the treatment of relapsed and refractory multiple myeloma (RRMM) within a real - world setting. We conducted a retrospective analysis of the clinical features and treatment outcomes of patients diagnosed with RRMM at the Union Hospital of Fujian Medical University from 2018 to 2024. The study cohort consisted of 62 patients, with a median age of 62 years. 80.6% of patients received one line therapy before administration of daratumumab. The median follow - up duration was 16.1 (1.9 - 69.6) months, and the median number of daratumumab treatment cycles was 7.5 (1 - 72) courses. Among the 56 evaluable cases, the overall response rate (ORR) was 89.3%, which included 11 cases (19.6%) attaining a stringent complete response (sCR) and 13 cases (23.2%) achieving a complete response (CR). The median progression free survival (PFS) of the entire cohort was 25.2 months. The 1 - year and 3 - year PFS rates were 75.2% and 25.4% respectively. The median overall survival (OS) was 42.7 months. The 1 - year and 3 - year OS rates were 84.2% and 62.8% respectively. Multivariate analysis indicated that poor performance status was independent unfavorable prognostic factors for PFS and OS. In conclusions, an early daratumumab - based treatment regimen has demonstrated promising therapeutic potential for treating RRMM and warrants further validation and exploration in future clinical practice.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"455-464"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review. 多形红斑作为派姆单抗治疗期间罕见的皮肤表现：1例报告和文献复习。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-09-01 Epub Date: 2025-06-02 DOI: 10.1080/1120009X.2025.2512264

G Silvi, E Rosi, I Scandagli, A Di Cesare, F Prignano

{"title":"Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review.","authors":"G Silvi, E Rosi, I Scandagli, A Di Cesare, F Prignano","doi":"10.1080/1120009X.2025.2512264","DOIUrl":"10.1080/1120009X.2025.2512264","url":null,"abstract":"We report the case of a 77-year-old man with recurrent oral squamous cell carcinoma who developed erythema multiforme (EM) following his third dose of pembrolizumab (PBZ). The patient presented with a widespread skin rash characterized by erythematous papules and plaques that evolved into targetoid lesions, with no mucosal involvement or systemic symptoms. The treatment with a tapering dose of prednisolone resolved the rash without interrupting PBZ therapy. The report reviews the existing literature on PBZ-induced EM as a rare cutaneous toxicity associated with immune-checkpoint inhibitors (ICIs). Prompt recognition and appropriate management of EM are crucial. The discussion emphasizes the importance of distinguishing it from more severe conditions such as toxic epidermal necrolysis or Stevens-Johnson syndrome. Decisions regarding the continuation of PBZ therapy should be made collaboratively by dermatologists and oncologists, considering the patient's overall health and cancer treatment plan.KEY POINTSImmune-checkpoint inhibitors like pembrolizumab have revolutionized cancer treatment, though skin toxicities can complicate therapy.EM is a rare side effect of pembrolizumab, occurring in only 0.1% of patients, usually without affecting mucous membranes.Cases of pembrolizumab-induced EM vary in severity but generally respond well to corticosteroids.Quick identification of EM is essential, and treatment continuation should be carefully considered based on cancer type and severity.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"501-505"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging trends in prostate cancer treatment: a systematic review of the literature. 前列腺癌治疗的新趋势：文献的系统回顾。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-08-20 DOI: 10.1080/1120009X.2026.2718574

Syeda Ayesha Fatima, Khawaja Husnain Haider, Sara Qutubuddin, Yousuf Begum, Margaret Stevenson, Khadija Fatima, Eman Ibrahim Anwar, Mayank Barg

{"title":"The emerging trends in prostate cancer treatment: a systematic review of the literature.","authors":"Syeda Ayesha Fatima, Khawaja Husnain Haider, Sara Qutubuddin, Yousuf Begum, Margaret Stevenson, Khadija Fatima, Eman Ibrahim Anwar, Mayank Barg","doi":"10.1080/1120009X.2026.2718574","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2718574","url":null,"abstract":"This Systematic review provides a comprehensive framework for understanding current therapeutic options and future directions in prostate cancer treatment. It highlights ongoing efforts, focusing on AR signaling inhibitors (ARSi) and novel molecularly targeted therapies. Using PRISMA-ScR guidelines, we conducted a comprehensive literature search across significant databases (MEDLINE/PubMed, Embase, and Cochrane Library). Next-generation ARSi (enzalutamide, apalutamide, darolutamide) have demonstrated significant survival benefits across various stages of prostate cancer, as evidenced by pivotal trials (PROSPER, SPARTAN, ARAMIS). The emergence of promising therapeutic approaches for biomarker-defined patient subgroups, including PARP inhibitors (PROfound, TRITON2), radioligand therapy (VISION, TheraP), and immunotherapy (KEYNOTE-199, CheckMate 650), is increasingly clinically relevant. While significant advances have been made in AR-targeted therapies, emerging molecular-targeted approaches are reshaping the treatment landscape. Our data provide a comprehensive framework for understanding current therapeutic options and future directions in prostate cancer treatment, engaging the audience and making them feel part of the solution.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-16"},"PeriodicalIF":2.1,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Six-month progression-free survival-related tumor growth rate after upfront chemotherapy as an outcome measure and potential prognostic or stratification variable for patients with unresectable pancreatic adenocarcinoma: an exploratory study cohorts analysis. 前期化疗后6个月无进展生存相关肿瘤生长率作为不可切除胰腺腺癌患者预后或分层变量的结局指标：一项探索性研究队列分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-08-16 DOI: 10.1080/1120009X.2026.2717469

Giuseppe A Colloca, Antonella Venturino

{"title":"Six-month progression-free survival-related tumor growth rate after upfront chemotherapy as an outcome measure and potential prognostic or stratification variable for patients with unresectable pancreatic adenocarcinoma: an exploratory study cohorts analysis.","authors":"Giuseppe A Colloca, Antonella Venturino","doi":"10.1080/1120009X.2026.2717469","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2717469","url":null,"abstract":"Overall survival (OS) has improved in unresectable/metastatic pancreatic adenocarcinoma (mPDAC) patients. However, it is unclear who should be offered further treatment, and how to assess the response in unmeasurable disease. The study aims to evaluate the role of 6-month progression-free survival (PFS) and the corresponding tumor growth rate after first-line chemotherapy (G6m). After identifying 15 randomized trials (19 cohorts, 4,725 patients), 6-month PFS were extracted from curves and expressed as G6m. Median G6m was higher after polychemotherapy and was significantly associated with OS (β = 0.168; p-value <0.001). The number of drugs and female sex correlated with a slower tumor growth rate. Since it was calculated directly from PFS in this study, it is not surprising that G6m exhibits a similar behavior. However, it can be derived by imaging or other markers, therefore representing a variable distinct from PFS, and as such warrants further evaluation in future studies.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenomic biomarkers in oncology: evidence, clinical utility, and barriers to implementation. 肿瘤学中的药物基因组生物标志物：证据、临床应用和实施障碍。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-08-06 DOI: 10.1080/1120009X.2026.2709952

Satyam Kumar Vishwash, Ram Babu Soni, Sourabh Kosey, Ratima Sood

引用次数: 0